| Title | DPP-4 Inhibitor Treatment in Chinese Type 2 Diabetes Patients: A Meta-Analysis |
| Authors | Cai, Xiaoling Gao, Xueying Yang, Wenjia Chen, Yifei Zhou, Lingli Zhang, Simin Han, Xueyao Ji, Linong |
| Affiliation | Peking Univ Peoples Hosp, Dept Endocrinol & Metab, 11 Xizhimen Nan Dajie, Beijing 100044, Peoples R China. |
| Keywords | Dipeptidyl peptidase-4 inhibitor Type 2 diabetes mellitus Chinese Meta-analysis ADD-ON THERAPY RANDOMIZED CONTROLLED-TRIAL DIPEPTIDYL PEPTIDASE-4 INHIBITORS IMPROVES GLYCEMIC CONTROL ORAL HYPOGLYCEMIC AGENTS CLINICAL-TRIAL DUAL COMBINATION ASIAN PATIENTS EFFICACY SAFETY |
| Issue Date | 2016 |
| Publisher | DIABETES TECHNOLOGY & THERAPEUTICS |
| Citation | DIABETES TECHNOLOGY & THERAPEUTICS.2016,18(12),784-793. |
| Abstract | Background: The aim of this meta-analysis was to assess the comprehensive clinical efficacy of dipeptidyl peptidase-IV (DPP-4) inhibitors in Chinese type 2 diabetes patients and to evaluate whether there is a different response to treatment with different kinds of DPP-4 inhibitors in those patients. Methods: Databases were systematically searched, and qualifying clinical studies of Chinese type 2 diabetes patients were included. Results: A total of 30 studies were included. Treatment with saxagliptin resulted in a significantly greater change from baseline in HbA1c levels (weighted mean difference [WMD], -1.28%; 95% CI, -1.37% to -1.19%); treatment with sitagliptin led to a significantly greater change from baseline (WMD, -1.17%; 95% CI, -1.46% to -0.89%); treatment with vildagliptin was associatedwith a significantly greater change in HbA(1c) levels (WMD, -0.77%; 95% CI, -0.88% to -0.65%); treatment with linagliptin led to a significantly greater change (WMD, -0.84%; 95% CI, -0.92% to -0.75%); and treatment with alogliptin also led to a significantly greater change (WMD, -0.91%; 95% CI, -1.48% to -0.33%). In terms of body weight, treatment with saxagliptin was associatedwith no significant decreases in Chinese type 2 diabetes mellitus (T2DM) patients (WMD, -0.17 kg, 95% CI, -4.26 to 3.92 kg). Treatment with sitagliptin and linagliptin was also associated with no significant changes in body weight (WMD, 0.16 and 0.11 kg, respectively, P>0.05). Conclusions: In Chinese type 2 diabetes patients, the efficacy of glucose control in all five kinds of DPP-4 inhibitor treatments was well confirmed, and no significant change in body weight was found. |
| URI | http://hdl.handle.net/20.500.11897/458176 |
| ISSN | 1520-9156 |
| DOI | 10.1089/dia.2016.0302 |
| Indexed | SCI(E) |
| Appears in Collections: | 人民医院 |
